The new factory, including a warehouse, will cover 40,000 square meters. Construction has already begun, and the facility is expected to be completed in 2027, according to a press release.
– We are proud to build on our legacy in Denmark and look forward to embarking on this journey in Odense, a well-connected city with a dynamic community and skilled workforce, says Henrik Wulff, Executive Vice President for Product Supply, Quality & IT at Novo Nordisk.
The investment is expected to create approximately 400 new jobs.
In addition, Novo Nordisk has received approval for its acquisition of the contract manufacturer Catalent for $11.7 billion. The acquisition means Novo Nordisk will take over Catalent's three pharmaceutical production facilities located in Italy, Belgium, and the USA.